Minimal Residual Disease Testing Market Growth and Forecast Report 2030

1
Minimal Residual Disease Testing Market Will
Reach USD 3,570.1 Million in 2030
2
In 2022, the minimal residual disease testing
market was worth around USD 1,156.8 million, and
it is projected to advance at a 15.1 CAGR from
2022 to 2030, hitting USD 3,570.1 million in
2030, according to PS Intelligence. This
development can be ascribed to the increasing
occurrence of solid tumors and hematological
malignancies. Furthermore, the rising healthcare
spending, also the increasing government and
private expenditure in minimal residual disease
studies, are projected to boost the growth of the
market in the future as well. For minimal
residual disease testing, next-generation
sequencing and polymerase chain reaction are the
most generally utilized methods, mainly because
they offer quick and more-precise outcomes than
others. Furthermore, businesses are concentrating
on the growth of innovative and enhanced assays
that will use these methods.
3
North America led the industry, by generating the
largest revenue share, of approximately 45 in
2022, mainly due to high RD and growth
expenditure, the existence of key players,
increasing acceptance of technologically enhanced
solutions, and the huge number of testing
amenities in the continent. The increasing
occurrence of cancer in the blood-making tissue
in the U.S. has surged the probability of
individuals possessing residual malignant cells,
which would support the requirement for minimal
residual disease testing. As per the American
Cancer Society, in 2022 in the U.S. approximately
34,470 new cases of multiple myeloma and 6,670
new cases of acute lymphocytic leukemia were
identified. Download sample pages of this
report https//www.psmarketresearch.com/market-an
alysis/minimal-residual-disease-testing-market/rep
ort-sample In the coming few years, the
hospital's category is projected to develop at
the highest rate, of more than 13 CAGR, in the
minimal residual disease testing market. This is
because of the existence of cutting-edge
diagnostic equipment, coupled with extremely
skilled healthcare specialists at such places.
4
The finding of the remaining cancerous cells
plays a vital role in creating up-to-date
long-term clinical decisions after the cancer
therapy is finished. Thus, the effectiveness of
the analysis is vital for healthcare insurance
businesses to offer financial aid to cancer
survivors globally. The hematological malignancy
category is projected to experience a CAGR of
over 16 in the coming few years, mainly because
of the increasing occurrence of leukemia
throughout the world. In 2022 as per the data
issued by the American Cancer Society, around
8,550 new cases of Hodgkins lymphoma were
identified in the U.S., with 3,970 females, and
4,570 males, along with 920 demises. Moreover,
survival rates have significantly amplified in
the past, mostly because of the enhancement in
the treatment, the effectiveness of which hinge
on the stage of cancer. Hence, the increasing
occurrence of solid tumors and hematological
malignancies, and also the rising healthcare
spending, also the increasing government and
private expenditure in minimal residual disease
studies, are driving the minimal residual disease
testing industry.
5
Disclaimer PS Intelligence always keeps its
customers interests at the core while carrying
out research activities. PS Intelligence ensures
the reliability and accuracy of information and
data provided in its market research
publications. However, the information in
publications is subject to fluctuations, as it is
based on primary interviews of officials from
various companies or organizations. PS
Intelligence is not responsible for any incorrect
data provided by the key industry players of the
concerned domain. the information or analysis in
PS Intelligence publications represents opinions
based on research and should not be interpreted
as statements of fact. Information in this report
was believed to be correct at the time of
publication, but cannot be guaranteed. PS
Intelligence does not endorse any product,
service, or vendor depicted in its research
publications. All intellectual properties,
including trademarks and copyrights, belong to
their respective owners and may be protected by
copyright. Under no circumstance can these be
reproduced in any form without prior written
agreement of their owners. An order for market
research report is intended for internal use of
the company only and not for disclosure to third
parties or any other publication in general. No
service, report, or part thereof provided by PS
Intelligence can be reproduced, republished,
resold, revealed, distributed, circulated, or
sublicensed in any medium or form now realized or
hereafter become realized, including but not
limited to, all forms of optical-based media,
magnetic, electronic, or digital, without a
written permission from Prescient Strategic
Intelligence Pvt. Ltd.